TISSUE REGENIX GROUP PLC — Board/Management Information 2017

Dec 1, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0705Y

Tissue Regenix Group PLC

01 December 2017

Tissue Regenix Group plc

Directorate Change

Leeds, 01 December 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, announces that the Board has accepted the resignation of Paul Devlin, CFO. The Board will commence a process to appoint a successor.

Steve Couldwell, CEO, Tissue Regenix Group commented: "Paul played a significant role throughout the fundraise and acquisition process, we wish him every success in the future."

Current trading remains in line with Board expectations.

For more Information:

Tissue Regenix Group plc Steve Couldwell                              CEO Caitlin Pearson                                Head of Communications	Tel: 0330 430 3073 / 07920272441
Jefferies International Ltd Simon Hardy / Christopher Binks	Tel:  020 7029 8000
FTI Consulting  Brett Pollard / Mo Noonan/ Rob Winder	Tel: 0203 727 1000

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAWGGRAGUPMPPU